Autolus Therapeutics plc's (NASDAQ:AUTL) Shares Bounce 28% But Its Business Still Trails The Industry

Autolus Therapeutics plc (NASDAQ:AUTL) shares have had a really impressive month, gaining 28% after a shaky period beforehand. Unfortunately, the gains of the last month did little to right the losses of the last year with the stock still down 29% over that time. In spite of the firm bounce in price, Autolus Therapeutics' price-to-sales (or "P/S") ratio of 8.5x might still make it look like a buy right now compared to the Biotechs industry in the United States, where around half of the companies have P/S ratios above 12.1x and even P/S above 84x are quite common. Nonetheless, we'd need to dig a little deeper to determine if there is a rational basis for the reduced P/S. We've found 21 US stocks that are forecast to pay a dividend yield of over 6% next year. See the full list for free. See our latest analysis for Autolus Therapeutics NasdaqGS:AUTL Price to Sales Ratio vs Industry December 20th 2025 How Autolus Therapeutics Has Been Performing Autolus Therapeutics certainly has been doing a good job lately as it's been growing revenue more than most other companies. One possibility is that the P/S ratio is low because investors think this strong revenue performance might be less impressive moving forward. If not, then existing shareholders have reason to be quite optimistic about the future direction of the share price. Want the full picture on analyst estimates for the company? Then our free report on Autolus Therapeutics will help you uncover what's on the horizon. What Are Revenue Growth Metrics Telling Us About The Low P/S? Autolus Therapeutics' P/S ratio would be typical for a company that's only expected to deliver limited growth, and importantly, perform worse than the industry. Taking a look back first, we see that the company's revenues underwent some rampant growth over the last 12 months. The latest three year period has also seen an incredible overall rise in revenue, aided by its incredible short-term performance. Accordingly, shareholders would have been over the moon with those medium-term rates of revenue growth. Turning to the outlook, the next three years should generate growth of 97% per annum as estimated by the nine analysts watching the company. With the industry predicted to deliver 130% growth per annum, the company is positioned for a weaker revenue result. With this information, we can see why Autolus Therapeutics is trading at a P/S lower than the industry. It seems most investors are expecting to see limited future growth and are only willing to pay a reduced amount for the stock. What Does Autolus Therapeutics' P/S Mean For Investors? Despite Autolus Therapeutics' share price climbing recently, its P/S still lags most other companies. Typically, we'd caution against reading too much into price-to-sales ratios when settling on investment decisions, though it can reveal plenty about what other market participants think about the company. As we suspected, our examination of Autolus Therapeutics' analyst forecasts revealed that its inferior revenue outlook is contributing to its low P/S. Right now shareholders are accepting the low P/S as they concede future revenue probably won't provide any pleasant surprises. It's hard to see the share price rising strongly in the near future under these circumstances. It is also worth noting that we have found 2 warning signs for Autolus Therapeutics that you need to take into consideration. If you're unsure about the strength of Autolus Therapeutics' business, why not explore our interactive list of stocks with solid business fundamentals for some other companies you may have missed. Mobile Infrastructure for Defense and DisasterThe next wave in robotics isn't humanoid. Its fully autonomous towers delivering 5G, ISR, and radar in under 30 minutes, anywhere.Get the investor briefing before the next round of contractsSponsored On Behalf of CiTech